SK Bioscience Co

SK Bioscience Co Enterprise Value

The Enterprise Value (EV) of SK Bioscience Co (302440.KS) as of Oct 28, 2026 is 4.33 T KRW. In the previous year, Enterprise Value (EV) was 4.25 T KRW — a change of 1.92% (higher).

Enterprise Value

4.33 TKRW

YoY

1.92%

Last updated:

Enterprise Value (EV) of SK Bioscience Co is 2025 4.33 T KRW. Enterprise Value (EV) of SK Bioscience Co was 2024 4.25 T KRW. It decreases by 1.92% higher compared to the previous year.

The SK Bioscience Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
3.99 T KRW
Jan 1, 2019
3.98 T KRW
Jan 1, 2020
3.97 T KRW
Jan 1, 2021
3.90 T KRW
Jan 1, 2022
3.86 T KRW
Jan 1, 2023
3.86 T KRW
Jan 1, 2024
4.25 T KRW
Jan 1, 2025
4.33 T KRW
The SK Bioscience Co Enterprise Value history
YEAREnterprise ValueYoY
4.33 TKRW+1.92%
4.25 TKRW+9.92%
3.86 TKRW0.00%
3.86 TKRW-0.91%
3.90 TKRW-1.68%
3.97 TKRW-0.36%
3.98 TKRW-0.23%
3.99 TKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Enterprise Value (EV) of SK Bioscience Co is 4.33 T KRW in 2025.

Enterprise Value (EV) of SK Bioscience Co changed from 4.25 T KRW to 4.33 T KRW, representing a 1.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SK Bioscience Co

All Key Metrics — SK Bioscience Co